purchase customization

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Neurodegenerative Disease
1.2 Key Market Segments
1.2.1 Neurodegenerative Disease Segment by Type
1.2.2 Neurodegenerative Disease Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Neurodegenerative Disease Market Overview
2.1 Global Market Overview
2.1.1 Global Neurodegenerative Disease Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Neurodegenerative Disease Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Neurodegenerative Disease Market Competitive Landscape
3.1 Global Neurodegenerative Disease Sales by Manufacturers (2019-2025)
3.2 Global Neurodegenerative Disease Revenue Market Share by Manufacturers (2019-2025)
3.3 Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Neurodegenerative Disease Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Neurodegenerative Disease Sales Sites, Area Served, Product Type
3.6 Neurodegenerative Disease Market Competitive Situation and Trends
3.6.1 Neurodegenerative Disease Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neurodegenerative Disease Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Neurodegenerative Disease Industry Chain Analysis
4.1 Neurodegenerative Disease Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Neurodegenerative Disease Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Neurodegenerative Disease Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Disease Sales Market Share by Type (2019-2025)
6.3 Global Neurodegenerative Disease Market Size Market Share by Type (2019-2025)
6.4 Global Neurodegenerative Disease Price by Type (2019-2025)
7 Neurodegenerative Disease Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Disease Market Sales by Application (2019-2025)
7.3 Global Neurodegenerative Disease Market Size (M USD) by Application (2019-2025)
7.4 Global Neurodegenerative Disease Sales Growth Rate by Application (2019-2025)
8 Neurodegenerative Disease Market Consumption by Region
8.1 Global Neurodegenerative Disease Sales by Region
8.1.1 Global Neurodegenerative Disease Sales by Region
8.1.2 Global Neurodegenerative Disease Sales Market Share by Region
8.2 North America
8.2.1 North America Neurodegenerative Disease Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neurodegenerative Disease Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Neurodegenerative Disease Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neurodegenerative Disease Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neurodegenerative Disease Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Neurodegenerative Disease Market Production by Region
9.1 Global Production of Neurodegenerative Disease by Region (2019-2025)
9.2 Global Neurodegenerative Disease Revenue Market Share by Region (2019-2025)
9.3 Global Neurodegenerative Disease Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Neurodegenerative Disease Production
9.4.1 North America Neurodegenerative Disease Production Growth Rate (2019-2025)
9.4.2 North America Neurodegenerative Disease Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Neurodegenerative Disease Production
9.5.1 Europe Neurodegenerative Disease Production Growth Rate (2019-2025)
9.5.2 Europe Neurodegenerative Disease Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Neurodegenerative Disease Production (2019-2025)
9.6.1 Japan Neurodegenerative Disease Production Growth Rate (2019-2025)
9.6.2 Japan Neurodegenerative Disease Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Neurodegenerative Disease Production (2019-2025)
9.7.1 China Neurodegenerative Disease Production Growth Rate (2019-2025)
9.7.2 China Neurodegenerative Disease Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Novartis
10.1.1 Novartis Neurodegenerative Disease Basic Information
10.1.2 Novartis Neurodegenerative Disease Product Overview
10.1.3 Novartis Neurodegenerative Disease Product Market Performance
10.1.4 Novartis Business Overview
10.1.5 Novartis Neurodegenerative Disease SWOT Analysis
10.1.6 Novartis Recent Developments
10.2 Pfizer
10.2.1 Pfizer Neurodegenerative Disease Basic Information
10.2.2 Pfizer Neurodegenerative Disease Product Overview
10.2.3 Pfizer Neurodegenerative Disease Product Market Performance
10.2.4 Pfizer Business Overview
10.2.5 Pfizer Neurodegenerative Disease SWOT Analysis
10.2.6 Pfizer Recent Developments
10.3 Merck Serono
10.3.1 Merck Serono Neurodegenerative Disease Basic Information
10.3.2 Merck Serono Neurodegenerative Disease Product Overview
10.3.3 Merck Serono Neurodegenerative Disease Product Market Performance
10.3.4 Merck Serono Neurodegenerative Disease SWOT Analysis
10.3.5 Merck Serono Business Overview
10.3.6 Merck Serono Recent Developments
10.4 Biogen Idec
10.4.1 Biogen Idec Neurodegenerative Disease Basic Information
10.4.2 Biogen Idec Neurodegenerative Disease Product Overview
10.4.3 Biogen Idec Neurodegenerative Disease Product Market Performance
10.4.4 Biogen Idec Business Overview
10.4.5 Biogen Idec Recent Developments
10.5 TEVA
10.5.1 TEVA Neurodegenerative Disease Basic Information
10.5.2 TEVA Neurodegenerative Disease Product Overview
10.5.3 TEVA Neurodegenerative Disease Product Market Performance
10.5.4 TEVA Business Overview
10.5.5 TEVA Recent Developments
10.6 UCB
10.6.1 UCB Neurodegenerative Disease Basic Information
10.6.2 UCB Neurodegenerative Disease Product Overview
10.6.3 UCB Neurodegenerative Disease Product Market Performance
10.6.4 UCB Business Overview
10.6.5 UCB Recent Developments
10.7 Boehringer Ingelheim
10.7.1 Boehringer Ingelheim Neurodegenerative Disease Basic Information
10.7.2 Boehringer Ingelheim Neurodegenerative Disease Product Overview
10.7.3 Boehringer Ingelheim Neurodegenerative Disease Product Market Performance
10.7.4 Boehringer Ingelheim Business Overview
10.7.5 Boehringer Ingelheim Recent Developments
10.8 Sanofi
10.8.1 Sanofi Neurodegenerative Disease Basic Information
10.8.2 Sanofi Neurodegenerative Disease Product Overview
10.8.3 Sanofi Neurodegenerative Disease Product Market Performance
10.8.4 Sanofi Business Overview
10.8.5 Sanofi Recent Developments
10.9 GlaxoSmithKline
10.9.1 GlaxoSmithKline Neurodegenerative Disease Basic Information
10.9.2 GlaxoSmithKline Neurodegenerative Disease Product Overview
10.9.3 GlaxoSmithKline Neurodegenerative Disease Product Market Performance
10.9.4 GlaxoSmithKline Business Overview
10.9.5 GlaxoSmithKline Recent Developments
10.10 Livzon Pharmaceutical
10.10.1 Livzon Pharmaceutical Neurodegenerative Disease Basic Information
10.10.2 Livzon Pharmaceutical Neurodegenerative Disease Product Overview
10.10.3 Livzon Pharmaceutical Neurodegenerative Disease Product Market Performance
10.10.4 Livzon Pharmaceutical Business Overview
10.10.5 Livzon Pharmaceutical Recent Developments
10.11 Haisco Pharmaceutical
10.11.1 Haisco Pharmaceutical Neurodegenerative Disease Basic Information
10.11.2 Haisco Pharmaceutical Neurodegenerative Disease Product Overview
10.11.3 Haisco Pharmaceutical Neurodegenerative Disease Product Market Performance
10.11.4 Haisco Pharmaceutical Business Overview
10.11.5 Haisco Pharmaceutical Recent Developments
10.12 Jingxin Pharmaceutical
10.12.1 Jingxin Pharmaceutical Neurodegenerative Disease Basic Information
10.12.2 Jingxin Pharmaceutical Neurodegenerative Disease Product Overview
10.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Product Market Performance
10.12.4 Jingxin Pharmaceutical Business Overview
10.12.5 Jingxin Pharmaceutical Recent Developments
10.13 Dongcheng Biochemicals
10.13.1 Dongcheng Biochemicals Neurodegenerative Disease Basic Information
10.13.2 Dongcheng Biochemicals Neurodegenerative Disease Product Overview
10.13.3 Dongcheng Biochemicals Neurodegenerative Disease Product Market Performance
10.13.4 Dongcheng Biochemicals Business Overview
10.13.5 Dongcheng Biochemicals Recent Developments
10.14 Hisun Pharmaceutical
10.14.1 Hisun Pharmaceutical Neurodegenerative Disease Basic Information
10.14.2 Hisun Pharmaceutical Neurodegenerative Disease Product Overview
10.14.3 Hisun Pharmaceutical Neurodegenerative Disease Product Market Performance
10.14.4 Hisun Pharmaceutical Business Overview
10.14.5 Hisun Pharmaceutical Recent Developments
10.15 Luye Pharma
10.15.1 Luye Pharma Neurodegenerative Disease Basic Information
10.15.2 Luye Pharma Neurodegenerative Disease Product Overview
10.15.3 Luye Pharma Neurodegenerative Disease Product Market Performance
10.15.4 Luye Pharma Business Overview
10.15.5 Luye Pharma Recent Developments
10.16 Ark Pharmaceutical
10.16.1 Ark Pharmaceutical Neurodegenerative Disease Basic Information
10.16.2 Ark Pharmaceutical Neurodegenerative Disease Product Overview
10.16.3 Ark Pharmaceutical Neurodegenerative Disease Product Market Performance
10.16.4 Ark Pharmaceutical Business Overview
10.16.5 Ark Pharmaceutical Recent Developments
10.17 Kanghong Pharmaceutical
10.17.1 Kanghong Pharmaceutical Neurodegenerative Disease Basic Information
10.17.2 Kanghong Pharmaceutical Neurodegenerative Disease Product Overview
10.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Product Market Performance
10.17.4 Kanghong Pharmaceutical Business Overview
10.17.5 Kanghong Pharmaceutical Recent Developments
10.18 Huahai Pharmaceutical
10.18.1 Huahai Pharmaceutical Neurodegenerative Disease Basic Information
10.18.2 Huahai Pharmaceutical Neurodegenerative Disease Product Overview
10.18.3 Huahai Pharmaceutical Neurodegenerative Disease Product Market Performance
10.18.4 Huahai Pharmaceutical Business Overview
10.18.5 Huahai Pharmaceutical Recent Developments
10.19 BORA PHARMACEUTICALS
10.19.1 BORA PHARMACEUTICALS Neurodegenerative Disease Basic Information
10.19.2 BORA PHARMACEUTICALS Neurodegenerative Disease Product Overview
10.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Product Market Performance
10.19.4 BORA PHARMACEUTICALS Business Overview
10.19.5 BORA PHARMACEUTICALS Recent Developments
11 Neurodegenerative Disease Market Forecast by Region
11.1 Global Neurodegenerative Disease Market Size Forecast
11.2 Global Neurodegenerative Disease Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurodegenerative Disease Market Size Forecast by Country
11.2.3 Asia Pacific Neurodegenerative Disease Market Size Forecast by Region
11.2.4 South America Neurodegenerative Disease Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Neurodegenerative Disease by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Neurodegenerative Disease Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Neurodegenerative Disease by Type (2025-2032)
12.1.2 Global Neurodegenerative Disease Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Neurodegenerative Disease by Type (2025-2032)
12.2 Global Neurodegenerative Disease Market Forecast by Application (2025-2032)
12.2.1 Global Neurodegenerative Disease Sales (K MT) Forecast by Application
12.2.2 Global Neurodegenerative Disease Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings